EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Medigen Vaccine Biologics EBITDA Margin % Related Terms
Medigen Vaccine Biologics EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6547 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Medigen Vaccine Biologics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigen Vaccine Biologics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigen Vaccine Biologics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Medigen Vaccine Biologics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medigen Vaccine Biologics (ROCO:6547) has a EBITDA Margin % of -68.10% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medigen Vaccine Biologics and its competitors. According to the industry distribution chart, Medigen Vaccine Biologics ranks #388 out of 944 companies in the Biotechnology industry, placing it in the top 41.1%.
Is Medigen Vaccine Biologics' EBITDA Margin % too high?
Medigen Vaccine Biologics' current EBITDA Margin % is -68.10%. Based on the distribution chart, Medigen Vaccine Biologics ranks #388 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Medigen Vaccine Biologics has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medigen Vaccine Biologics' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medigen Vaccine Biologics ranks #388 out of 944 companies for EBITDA Margin %. This puts Medigen Vaccine Biologics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medigen Vaccine Biologics and its competitors. Medigen Vaccine Biologics's current EBITDA Margin % is -68.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Vaccine Biologics stock overvalued right now?
Based on GuruFocus' analysis, Medigen Vaccine Biologics (ROCO:6547) is currently considered Possible Value Trap. The stock's GF Value™ is NT$69.49, compared to a current price of NT$45.45 — trading 34.6% below its estimated fair value. The current EBITDA Margin % is -68.10%. Medigen Vaccine Biologics' overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Medigen Vaccine Biologics (ROCO:6547), the current EBITDA Margin % is -68.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medigen Vaccine Biologics (ROCO:6547) Overvalued in 2026?
Based on GuruFocus' analysis, Medigen Vaccine Biologics stock appears to be undervalued.
The current stock price of NT$45.45 is trading 34.6% below its estimated GF Value™ of NT$69.49.
GuruFocus considers Medigen Vaccine Biologics to be Possible Value Trap.
Key valuation signals for ROCO:6547:
EBITDA Margin %: -68.10%
GF Value™: NT$69.49 vs. price of NT$45.45 (34.6% below fair value)
No single metric tells the full story. See the ROCO:6547 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medigen Vaccine Biologics Corp is engaged in the research, development and wholesale of vaccine and biopharmaceutical, medical devices wholesale and retail, etc. Its products include dengue vaccine, anti-RSV biosimilars, COVID-19 vaccines, enterovirus A71 vaccine, and influenza vaccine QIZ. It operates business only in a single industry in Taiwan.
68GF Score
Get the complete analysis for ROCO:6547
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6547 has been successfully added to your 
